Dose-response trial of megestrol acetate in advanced breast cancer: Cancer and leukemia group B phase III study 8741 Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Breast Neoplasms
  • Megestrol Acetate

abstract

  • With a median follow-up of 8 years, these results demonstrate no advantage for dose escalation of MA in the treatment of metastatic breast cancer.

publication date

  • January 1999

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10458219

Additional Document Info

start page

  • 64

end page

  • 73

volume

  • 17

number

  • 1